{"id":"https://openalex.org/W2078614301","doi":"https://doi.org/10.1038/sj.bjc.6603317","title":"ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia","display_name":"ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia","alternate_titles":[],"publication_year":2006,"publication_date":"2006-09-05","ids":{"openalex":"https://openalex.org/W2078614301","doi":"https://doi.org/10.1038/sj.bjc.6603317","mag":"2078614301","pmid":"https://pubmed.ncbi.nlm.nih.gov/16953242","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2360538"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjc.6603317","doi":"https://doi.org/10.1038/sj.bjc.6603317","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603317","pdf_url":"https://www.nature.com/articles/6603317.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2078614301"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/6603317.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022067885","display_name":"Danilo Perrotti","orcid":"https://orcid.org/0000-0003-0726-8766","observed_orcids":["https://orcid.org/0000-0003-0726-8766"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"D Perrotti","raw_affiliation_strings":["Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. danilo.perrotti@osumc.edu","Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. danilo.perrotti@osumc.edu","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061158509","display_name":"Paolo Neviani","orcid":"https://orcid.org/0000-0002-5923-2522","observed_orcids":["https://orcid.org/0000-0002-5923-2522"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P Neviani","raw_affiliation_strings":["Department of Molecular Virology, Human Cancer Genetics Program, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, 43210, OH, USA","Department of Molecular Virology, Human Cancer Genetics Program, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Virology, Human Cancer Genetics Program, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, 43210, OH, USA","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"Department of Molecular Virology, Human Cancer Genetics Program, Immunology and Medical Genetics, and The Comprehensive Cancer Center, The Ohio State University, Columbus, USA","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5022067885"],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":0.612,"has_fulltext":true,"cited_by_count":60,"citation_normalized_percentile":{"value":0.51921275,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"95","issue":"7","first_page":"775","last_page":"781"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.00279999990016222,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/protein-phosphatase-2a","display_name":"protein phosphatase 2A","score":0.9290000200271606},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9629999995231628},{"id":"https://openalex.org/keywords/blast-crisis","display_name":"blast crisis","score":0.9800000190734863},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.9990000128746033},{"id":"https://openalex.org/keywords/bcr-abl","display_name":"BCR-ABL","score":0.7450000047683716},{"id":"https://openalex.org/keywords/t315i-mutation","display_name":"T315I mutation","score":0.8970000147819519},{"id":"https://openalex.org/keywords/leukemia-stem-cells","display_name":"leukemia stem cells","score":0.8939999938011169},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7639999985694885},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5410000085830688},{"id":"https://openalex.org/keywords/clonogenicity","display_name":"clonogenicity","score":0.8790000081062317},{"id":"https://openalex.org/keywords/leukemogenesis","display_name":"leukemogenesis","score":0.7720000147819519},{"id":"https://openalex.org/keywords/kinase-inhibitors","display_name":"kinase inhibitors","score":0.32499998807907104}],"concepts":[{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7685707211494446},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.7570724487304688},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.7348004579544067},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6378299593925476},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5835093259811401},{"id":"https://openalex.org/C117262875","wikidata":"https://www.wikidata.org/wiki/Q5135057","display_name":"Clonogenic assay","level":3,"score":0.4291073977947235},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3847346901893616},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3816799521446228},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.2978828549385071},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22599244117736816},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.15365692973136902},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001752","descriptor_name":"Blast Crisis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010749","descriptor_name":"Phosphoprotein Phosphatases","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010749","descriptor_name":"Phosphoprotein Phosphatases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D016313","descriptor_name":"Genes, abl","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D051562","descriptor_name":"Proto-Oncogene Proteins c-bcr","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D054648","descriptor_name":"Protein Phosphatase 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1038/sj.bjc.6603317","doi":"https://doi.org/10.1038/sj.bjc.6603317","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603317","pdf_url":"https://www.nature.com/articles/6603317.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2360538","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2360538/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:16953242","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16953242","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.281.3842","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.281.3842","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/9a/a6/Br_J_Cancer_2006_Oct_9_95(7)_775-781.tar.gz","raw_type":"text"}],"best_oa_location":{"id":"doi:10.1038/sj.bjc.6603317","doi":"https://doi.org/10.1038/sj.bjc.6603317","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjc.6603317","pdf_url":"https://www.nature.com/articles/6603317.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7830551707","display_name":"Role of RNA Binding Proteins in BCR/ABL Leukemogenesis","funder_award_id":"R01CA095512","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332447","display_name":"U.S. Army","ror":"https://ror.org/00afsp483"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2078614301.pdf","grobid_xml":"https://content.openalex.org/works/W2078614301.grobid-xml"},"referenced_works_count":77,"referenced_works":["https://openalex.org/W96068813","https://openalex.org/W1490973221","https://openalex.org/W1576014737","https://openalex.org/W1639582946","https://openalex.org/W1867818836","https://openalex.org/W1963579207","https://openalex.org/W1964504843","https://openalex.org/W1964695733","https://openalex.org/W1964739066","https://openalex.org/W1964957919","https://openalex.org/W1968172659","https://openalex.org/W1973720500","https://openalex.org/W1974715440","https://openalex.org/W1977712070","https://openalex.org/W1980073676","https://openalex.org/W1981076681","https://openalex.org/W1981083415","https://openalex.org/W1981427383","https://openalex.org/W1984235698","https://openalex.org/W1988446426","https://openalex.org/W1994309500","https://openalex.org/W1997664222","https://openalex.org/W1999793253","https://openalex.org/W2000779490","https://openalex.org/W2001600598","https://openalex.org/W2003177342","https://openalex.org/W2008198386","https://openalex.org/W2010800752","https://openalex.org/W2012962381","https://openalex.org/W2013091180","https://openalex.org/W2016086822","https://openalex.org/W2021029116","https://openalex.org/W2023544072","https://openalex.org/W2031255542","https://openalex.org/W2031594339","https://openalex.org/W2038538605","https://openalex.org/W2039787813","https://openalex.org/W2039898346","https://openalex.org/W2043024617","https://openalex.org/W2044838118","https://openalex.org/W2052875624","https://openalex.org/W2053922479","https://openalex.org/W2054177883","https://openalex.org/W2055910783","https://openalex.org/W2057599008","https://openalex.org/W2058576674","https://openalex.org/W2061243113","https://openalex.org/W2066893159","https://openalex.org/W2070067474","https://openalex.org/W2071006062","https://openalex.org/W2072462194","https://openalex.org/W2073640953","https://openalex.org/W2079517811","https://openalex.org/W2082661266","https://openalex.org/W2090004346","https://openalex.org/W2094185359","https://openalex.org/W2095443553","https://openalex.org/W2097946794","https://openalex.org/W2105214585","https://openalex.org/W2110003347","https://openalex.org/W2113113373","https://openalex.org/W2116247281","https://openalex.org/W2117569938","https://openalex.org/W2124193450","https://openalex.org/W2129541995","https://openalex.org/W2149468947","https://openalex.org/W2155205071","https://openalex.org/W2159382428","https://openalex.org/W2159863363","https://openalex.org/W2164627733","https://openalex.org/W2164910466","https://openalex.org/W2165142542","https://openalex.org/W2166830325","https://openalex.org/W2167522647","https://openalex.org/W2324425957","https://openalex.org/W2403235282","https://openalex.org/W2555977518"],"related_works":["https://openalex.org/W7028227900","https://openalex.org/W2979483347","https://openalex.org/W1981083415","https://openalex.org/W2752073938","https://openalex.org/W4240190529","https://openalex.org/W2592807902","https://openalex.org/W3146790579","https://openalex.org/W2082935152","https://openalex.org/W2560039739"],"abstract_inverted_index":{"The":[0],"deregulated":[1],"kinase":[2,28],"activity":[3,118],"of":[4,8,34,43,101,111,119,142,159,177],"p210-BCR/ABL":[5],"oncoproteins,":[6],"hallmark":[7],"chronic":[9,35],"myelogenous":[10],"leukaemia":[11,75],"(CML),":[12],"induces":[13],"and":[14,19,107,136,154,161,180],"sustains":[15],"the":[16,73,99,117,120,175],"leukaemic":[17],"phenotype,":[18],"contributes":[20],"to":[21,48,53,63,81,146],"disease":[22,57],"progression.":[23],"Imatinib":[24],"mesylate,":[25],"a":[26,40,56,87,186],"BCR/ABL":[27,181],"inhibitor,":[29],"is":[30,60,68,78,85,127],"effective":[31],"in":[32,130,156],"most":[33],"phase":[36],"CML":[37,44,74,133,193],"patients.":[38,194],"However,":[39],"significant":[41],"percentage":[42],"patients":[45],"develop":[46],"resistance":[47,106],"imatinib":[49,64,105],"and/or":[50,168],"still":[51,86],"progresses":[52],"blast":[54,131,191],"crisis,":[55],"stage":[58],"that":[59,72,116,137],"often":[61],"refractory":[62],"therapy.":[65],"Furthermore,":[66],"there":[67,84],"compelling":[69],"evidence":[70],"indicating":[71],"stem":[76],"cell":[77,172],"also":[79],"resistant":[80],"imatinib.":[82],"Thus,":[83,174],"need":[88],"for":[89,190],"new":[90],"drugs":[91,183],"that,":[92],"if":[93],"combined":[94],"with":[95],"imatinib,":[96],"will":[97],"decrease":[98],"rate":[100],"relapse,":[102],"fully":[103],"overcome":[104],"prevent":[108],"blastic":[109],"transformation":[110],"CML.":[112],"We":[113],"recently":[114],"reported":[115],"tumour":[121],"suppressor":[122],"protein":[123],"phosphatase":[124,144],"2A":[125],"(PP2A)":[126],"markedly":[128],"inhibited":[129],"crisis":[132,192],"patient":[134,166],"cells":[135,167],"molecular":[138],"or":[139],"pharmacologic":[140],"re-activation":[141],"PP2A":[143,178],"led":[145],"growth":[147],"suppression,":[148],"enhanced":[149],"apoptosis,":[150],"impaired":[151],"clonogenic":[152],"potential":[153],"decreased":[155],"vivo":[157],"leukaemogenesis":[158],"imatinib-sensitive":[160],"-resistant":[162],"(T315I":[163],"included)":[164],"CML-BC":[165],"BCR/ABL+":[169],"myeloid":[170],"progenitor":[171],"lines.":[173],"combination":[176],"phosphatase-activating":[179],"kinase-inhibiting":[182],"may":[184],"represent":[185],"powerful":[187],"therapeutic":[188],"strategy":[189]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2078614301","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
